Left behind: Should minimal residual disease be treated in hairy cell leukemia?

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 971-972

  Park, Jae H ^a   Tallman, Martin S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; PENTOSTATIN; RITUXIMAB; VEMURAFENIB;

CLINICAL TRIAL (TOPIC); FLOW CYTOMETRY; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; NOTE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; FEMALE; LEUKEMIA, HAIRY CELL; MALE;

CLADRIBINE; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; PENTOSTATIN;

EID: 84899709227     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.866667     Document Type: Note

References (25)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis . Blood 1958; 13: 609-630.
2. Quesada JR, Reuben J, Manning JT, et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310: 15-18.
3. Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: Induction of complete remission with pentostatin (2 '-deoxycoformycin). J Clin Oncol 1984; 2: 1336-1342.
4. Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairycell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117-1121.
5. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21: 891-896.
6. Chadha P, Rademaker A W, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): Long-Term follow-up of the Northwestern University experience. Blood 2005; 106: 241-246.
7. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-Term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96: 2981-2986.
8. Else M, Ruchlemer R, Osuju N, et al. Long remissions in hairy cell leukemia with purine analogs: A report of 219 patients with a median follow-up of 125 years. Cancer 2005; 104: 2442-2448.
9. Lopez Rubio M, Da Silva C, Loscertales J, et al. Hairy cell leukemia treated initially with purine analogs: A retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leuk Lymphoma 2014; 55: 1007-1012.
10. Sausville JE, Salloum RG, Sorbara L, et al. Minimal residual disease detection in hairy cell leukemia Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003; 119: 213-217.
11. Bengio R, Narbaitz MI, Sarmiento MA, et al. Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia. Haematologica 2000; 85: 1227-1229.
12. Tallman M S, Hakimian D, Kopecky K J, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999; 5: 1665-1670.
13. Sigal DS, Sharpe R, Burian C, et al. Very long-Term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010; 115: 1893-1896.
14. Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84: 4310-4315.
15. Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years followup after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: Evaluation of minimal residual disease and CD4-lymphocytopenia after treatment. Leuk Lymphoma 1999; 35: 555-565.
16. Wheaton S, Tallman MS, Hakimian D, et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87: 1556-1560.
17. Matutes E, Meeus P, McLennan K, et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: A long-Term follow-up study. Br J Haematol 1997; 98: 375-383.
18. Ravandi F, Jorgensen JL, O ' Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107: 4658-4662.
19. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: Extended follow-up. Br J Haematol 2008; 143: 296-298.
20. Tiacci E, Trifonov V, Sciavoni G, et al. BRAF mutations in hairycell leukemia. N Engl J Med 2011; 364: 2305-2315.
21. Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012; 119: 188-191.
22. Schnittger S, Bacher U, Haferlach T, et al. Development and validation of a real-Time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood 2012; 119: 3151-3154.
23. Akarca AU, Shende VH, Ramsay AD, et al. BRAF V600E mutationspecific antibody, asensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol 2013; 162: 848-851.
24. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366: 2038-2040.
25. Munoz J, Schlette E, Kurzrock R. R apid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 2013; 31: E351-e352.